Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis
Alderuccio J, Beaven A, Shouse G, Epperla N, Stefanovic A, Torka P, Castillo J, Argnani L, Voorhees T, Alpert A, Chowdhury S, Reis I, Zhao W, Edwards D, Martin P, Kamdar M, Herrera A, Friedberg J, Zinzani P, Lossos I. Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-137620.Peer-Reviewed Original ResearchExtranodal marginal zone lymphomaEntity's Board of DirectorsIncidence of infectious complicationsMarginal zone lymphomaNo survival differenceRituximab maintenanceOverall survivalMALT-IPIInfectious complicationsSurvival differencesBone marrowPrognostic factors associated with worse outcomesADC therapeuticsIncidence of herpes zoster infectionECOG performance status 0Cases of acute myeloid leukemiaFactors associated with worse outcomesNon-gastric locationPerformance status 0ECOG performance statusGastric extranodal marginal zone lymphomaExpert pathology reviewHerpes zoster infectionMajority of patientsLog-rank test